September 14, 2016
Posted September 20, 2016
Healthmark Investment Trust, partial owner of Florida-based compound pharmacy QMedRx, agreed to pay $7.75 million to resolve allegations QMedRx violated the False Claims Act by billing the federal healthcare programs for prescriptions tainted within the meaning of the Anti-Kickback Statute. The government is still pursuing penalties and fines from other owners and participants within QMedRx. DOJ (MDFL)
Tagged in: Anti-Kickback and Stark, Compounding Pharmacy Fraud, FCA Federal, Other Government Health Programs,